| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
103 |
| Employees |
120 |
| Revenues (TTM) (Millions $) |
167 |
| Net Income (TTM) (Millions $) |
85 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Biodelivery Sciences International Inc (BDSI) is a pharmaceutical company based in Raleigh, North Carolina, focused on developing and commercializing innovative treatments for chronic pain, addiction, and other central nervous system disorders using its proprietary delivery technologies.
The company was founded in 1997 as BioDelivery Technologies Inc. and changed its name to BDSI in 2009. Its core technologies include BioErodible MucoAdhesive (BEMA) and Bioral platforms, which are designed to improve the delivery of drugs into the bloodstream through oral and transmucosal routes, respectively.
BDSI's current commercialized products include Belbuca (buprenorphine buccal film), which is used for chronic pain management, and Bunavail (buprenorphine and naloxone buccal film), which is used for medication-assisted treatment of opioid addiction. The company also has a pipeline of products in various stages of development, including Clonidine Topical Gel for diabetic neuropathy and a long-acting version of buprenorphine for chronic pain management.
In addition to its proprietary technologies, BDSI also has established partnerships with several pharmaceutical companies, including Endo Pharmaceuticals and Meda Pharmaceuticals, to develop and commercialize new products.
BDSI's management team includes experienced professionals with backgrounds in pharmaceuticals, business, and finance. The company is committed to innovation and improving patient care, and its technologies and products have received recognition from healthcare professionals and patients alike.
Company Address: 4131 ParkLake Avenue, Suite 225, Raleigh 27612 NC
Company Phone Number: 582-9050 Stock Exchange / Ticker: NASDAQ BDSI
|
%
5.06%